It is highly significant to explore potentials of these medications to delay the clinical onset of AD and provide a window of opportunity for therapeutic intervention, regardless of the eligibility of these patients for Leqembi.
← all excerpts
The Comparative Effectiveness of Monotherapy and Combination Therapies: Impact of Angiotensin Receptor Blockers on the Onset of Alzheimer's Disease.
1
—
—